-

Hologic to Webcast Presentation at the 40th Annual J.P. Morgan Healthcare Conference

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30 p.m. Eastern Time.

The presentation and Q&A session will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcast will be available for 30 days following the event.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Senior Investor Relations Specialist
(858) 410-8904
paula.izidoro@hologic.com

Industry:

Hologic, Inc.

NASDAQ:HOLX
Release Summary
Hologic to Webcast Presentation at the 40th Annual J.P. Morgan Healthcare Conference
Release Versions
English
Hashtags
#HOLX
#JPMorganconference
#hologic
#presentation

Contacts

Paula Izidoro
Senior Investor Relations Specialist
(858) 410-8904
paula.izidoro@hologic.com

More News From Hologic, Inc.

Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026...

Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening...

Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams...
Back to Newsroom